NYSE:VOR

Vor Biopharma (VOR) Stock Price, News & Analysis

$1.74
-0.14 (-7.45%)
(As of 04/24/2024 ET)
Today's Range
$1.73
$1.87
50-Day Range
$1.68
$2.37
52-Week Range
$1.62
$5.70
Volume
286,829 shs
Average Volume
293,442 shs
Market Capitalization
$118.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50

Vor Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
675.9% Upside
$13.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Vor Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.34) to ($1.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.49 out of 5 stars

Medical Sector

372nd out of 909 stocks

VOR stock logo

About Vor Biopharma Stock (NYSE:VOR)

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

VOR Stock Price History

VOR Stock News Headlines

Vor Biopharma (NYSE:VOR) Trading Down 5.3%
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Vor Biopharma: Q4 Earnings Insights
VOR Apr 2024 5.000 call
See More Headlines
Receive VOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/24/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
N/A
Sub-Industry
N/A
Fax
N/A
Employees
168
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.50
High Stock Price Target
$17.50
Low Stock Price Target
$11.00
Potential Upside/Downside
+675.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
54,300,000
Market Cap
$118.70 million
Optionable
Not Optionable
Beta
-0.36
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Robert Ang M.B.A. (Age 49)
    M.D., MBBS, President, CEO & Director
    Comp: $943.91k
  • Mr. Samir Vattompadam M.S.
    Senior Vice President of Portfolio Strategy & Program Management
  • Mr. David Phillips M.B.A.
    Senior VP & Head of Quality

VOR Stock Analysis - Frequently Asked Questions

Should I buy or sell Vor Biopharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vor Biopharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VOR shares.
View VOR analyst ratings
or view top-rated stocks.

What is Vor Biopharma's stock price target for 2024?

5 brokers have issued 1 year price targets for Vor Biopharma's stock. Their VOR share price targets range from $11.00 to $17.50. On average, they expect the company's stock price to reach $13.50 in the next year. This suggests a possible upside of 675.9% from the stock's current price.
View analysts price targets for VOR
or view top-rated stocks among Wall Street analysts.

How have VOR shares performed in 2024?

Vor Biopharma's stock was trading at $2.25 at the start of the year. Since then, VOR shares have decreased by 22.7% and is now trading at $1.74.
View the best growth stocks for 2024 here
.

When is Vor Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VOR earnings forecast
.

How were Vor Biopharma's earnings last quarter?

Vor Biopharma Inc. (NYSE:VOR) posted its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.10.

What ETFs hold Vor Biopharma's stock?

ETFs with the largest weight of Vor Biopharma (NYSE:VOR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

When did Vor Biopharma IPO?

Vor Biopharma (VOR) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel acted as the underwriters for the IPO.

How do I buy shares of Vor Biopharma?

Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:VOR) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners